“showed a trend”

cfDNA high (>4.19 log 10 hGE/mL) significantly predicted OS rates ( p = 0.043, HR:3.42[0.96–12.15]) and showed a trend towards inferior FFS ( p = 0.25, HR:1.82[0.65–5.05]) (Fig. 2B, C ).

At 4 months post-therapy, animals in the S-CDCs group showed a trend towards higher LVEF than the swine belonging to CON group (35 ± 10% vs. 29 ± 10%, p = 0.25) ( Figure 3 A).

Although the mean FEV1 also showed a trend towards improvement, from 2.4 litres (SD 0.94) to FEV1 2.73 litres (SD 0.88), the difference was not statistically significant (p=0.25) (Table 2 ).

In non‐gastrointestinal stromal tumor sarcomas, the dual test showed a trend toward higher rates of genotype‐matched therapy (4.3% vs. 2.6%, p = 0.25) and a significantly higher rate of molecular targeted therapy (4.3% vs. 1.5%, p = 0.03).

The covariables included were those that showed a trend of difference ( P <0.25) in baseline characteristics between the CMED and non‐CMED group.

Patients whose tumors retained membrane claudin 1 expression in more than 10% of the tumor cells showed a trend towards increased survival (Kaplan-Meier analysis, p=0.25).

Survivors in our study showed a trend for shorter reperfusion times (minutes: 83.3 ± 40.6 vs. 98.4 ± 40.5; p = 0.25) and total CBP times (minutes: 215.8 ± 73.6 vs. 256.2 ± 125.9; p = 0.26) with a significantly shorter total operation time (minutes: 364.6 ± 97.1 vs. 449.1 ± 141.7; p = 0.002).

This unfavorable prognostic effect occurred in MSS/MSI-L ( p = 0.0532) and showed a trend in MSI-H ( p = 0.2515; Figures 3 B,C).

Alpha-diversity analysis showed a trend of elevation in microbial richness ( P = 0.253 for observed OTUs index and P = 0.175 for Shannon) in AF mice compared with PF mice, while IL-22 treatment to AF mice had the highest levels of both alpha-diversity indexes ( Figure 4A ).

In this subgroup, TMB showed a trend toward a positive but weak correlation ( r = 0.377; p = .253) with PFS on anti‐PD1 treatment (Fig. 2A ).

Among the PWE+OSA group, the low rAT subgroup showed a trend toward lower body weight (p = 0.255), lower BMI (p = 0.256), and lower NC (p = 0.124) compared to the high rAT subgroup, although these differences did not reach statistical significance.

A sensitivity analysis excluding Tamene et al.’s study [ 9 ] showed a trend reversal, favoring lower-educated workers, with an RR of 0.47 (95% CI: 0.29–0.77, p = 0.2562; I 2 = 26.6%).

Preliminary findings showed a trend towards better PFS in the high-dose arm [19.9 vs 14.4 mo, hazard ratio (HR) 0.8, P = 0.257], with a significantly higher median OS in that same arm (41.6 mo vs 22.9 mo, HR 0.63; P = 0.027).

5.3 months, p = 0.044) and showed a trend toward shorter OS (5.7 vs. 12.3 months, p = 0.257) compared to those with AFP <400 ng/mL ( Fig. 3 c, d).

Our regimen showed a trend of lower rates of marginal recurrence, and the brain volume of high-dose radiation fields in our regimen was similar to that of EORTC (p = 0.257).

In a further retrospective multicenter study, patients treated with tebe following ICB showed a trend for a prolonged OS compared to patients treated with second-line ICB after tebe therapy (28 vs. 24 months, p = 0.257) [ 42 ].

Dissociation of ex vivo primary ccRCC samples showed a trend (p = 0.258) to an increased proportion of Annexin-V neg /DAPI neg /CD45 neg cells in the presence of 10 μM Y-27632 ( Fig. 5B ).

Using The Cancer Genome Atlas (TCGA) 23 – 25 entire data set of cervical adenocarcinomas with available transcriptome and outcome data (n = 26), we modeled this four-gene score as a continuous predictor of outcome using a univariate Cox proportional hazards model, which showed a trend towards higher four-gene expression being associated with worse outcome (hazard ratio 2.17, 95% confidence interval 0.57–8.31, p-value = 0.258).

The LUAD cohort of TCGA also showed a trend of longer OS in CTNNA2-MT patients (log-rank test, p = 0.258), and the trend of longer disease-free survival (DFS) was also observed in CTNNA2-MT patients (log-rank test, p = 0.059) ( Figure 6A ).

Heterozygous patients showed a trend towards an increased risk of melanoma death (HR 1.46 [95% CI 0.76–2.83], p = 0.26).

However, active SLE patients showed a trend of higher frequency of calcitriol serum levels in the third tertile ( T 3 rd = 50%) compared to inactive SLE patients ( p = 0.26) ( Table 1 ).

Normotensive major allele homozygotes for SGK1 showed a trend towards higher BP on a high salt diet, albeit not significant ( rs2758151 : 109.2 ± 3.3 mmHg; 108.8 ± 3.3 mmHg; 105.3 ± 4.0 mmHg, p = 0.26; rs9402571 : 109.0 ± 3.2 mmHg; 107.6 ± 3.3 mmHg; 104.8 ± 6.3 mmHg, p = 0.32).

Furthermore, GREB1 also showed a trend of overexpression in platinum sensitive samples, regardless of PARP level ( P = .26).

In contrast, combination treatment with TACE + RFA showed a trend towards improved survival compared with no treatment (67.1% vs 63.3%, p=0.26, Figure 5 ) but did not reach statistical significance.

However, ESV between Wk8 and M6 was not different in DFP+/IMH+ group ( p = 0.49), while ESV showed a trend towards increasing between Wk8 and M6 in DFP−/IMH+ group ( p = 0.26).